Walgreens Boots Alliance Reports Q3 Loss Amid Sales Growth and Strategic Restructuring Efforts

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) has reported its Q3 results for the fiscal year ending May 31, 2025, showcasing significant shifts in its financial health.

• Sales Growth: Total sales saw a strong increase, rising by 7.2% to reach $38.986 billion in Q3 2025 compared to $36.351 billion in Q3 2024. Year-to-date sales reached $117.034 billion, up from $110.111 billion.
• Cost of Sales: Cost of sales increased to $32.480 billion in Q3 2025, leading to a gross profit of $6.506 billion, slightly up from $6.460 billion in the previous year.
• Selling, General and Administrative (SG&A) Expenses: SG&A expenses increased to $6.493 billion from $6.393 billion.
• Net Loss: The company reported a net loss of $175 million compared to earnings of $344 million in the prior year, with a net loss per share dropping from $0.40 to $0.20.
• Operating Income: Operating income fell to $53 million compared to $111 million, largely due to higher expenses and reduced retail sales.
• Goodwill Impairment: There was no impairment charge for Q3 2025; however, a significant impairment of $3.653 billion was recorded in the nine-month period, reflecting ongoing challenges at VillageMD and other segments.
• Cash Position: Cash, cash equivalents, and restricted cash totaled $939 million as of May 31, 2025, down from $3.218 billion at the end of the previous fiscal year.
• Debt Management: Total outstanding debt as of May 31, 2025, stood at $7.366 billion, indicating an effort to streamline financial obligations.
• Dividends Suspended: The Board suspended the quarterly cash dividend to manage capital allocation and enhance cash flow amid restructuring efforts.
• Strategic Initiatives: The ongoing Footprint Optimization Program aims to close 900 to 1,000 underperforming stores by fiscal 2027, with 423 stores already closed.
• Upcoming Merger: A notable development is the planned merger with Blazing Star Parent, LLC, which is expected to finalize in the second half of 2025, valuing the company at $11.45 per share in cash.

The income statement reveals contrasts between growth opportunities and underlying operational challenges, as Walgreens Boots Alliance navigates a pivotal period in its restructuring and adaptation strategies in the retail pharmacy landscape.